Dr Bertrand Drugeon1,2,3,6,7, Claire Rickard1,2,3,4,5, Amanda Ullman1,2,4,5,8, Nicole Marsh1,2,4,5, Amanda Corley1,2,4,5, Daner Ball1,2,3, Catherine O’Brien1,4,5, Tricia M Kleidon1,2,4,5,8, Jérémy Guenezan6,7,9, Raphaël Couvreur6, Kate McCarthy10,11, Sabrina Seguin6, Guillaume Batiot6, Josh Byrnes3,11, Jessica Schults1,2,3,8, Syeda Farah Zahir12, Olivier Mimoz6,7,9
1AVATAR Group, Griffith University, Brisbane, Australia, 2School of Nursing, Midwifery and Social Work, University of Queensland, Brisbane, Australia, 3Herston Infectious Diseases Institute, Metro North Health, Brisbane, Australia, 4School of Nursing and Midwifery, Griffith University, Brisbane, Australia, 5Nursing and Midwifery Research Centre, Royal Brisbane and Women’s Hospital, Brisbane, Australia, 6CHU de Poitiers, Service des Urgences Adultes-SAMU 86-Centre 15, Poitiers, France, 7INSERM, U1070, Pharmacologie des Agents anti-Infectieux, Poitiers, France, 8Queensland Children’s Hospital, Children’s Health Queensland Hospital and Health Service, Brisbane, France, 9Université de Poitiers, UFR de Médecine Pharmacie, Poitiers, France, 10Department of Infectious Diseases, Royal Brisbane and Women’s Hospital, Brisbane, Australia, 11Centre for Applied Health Economics, Griffith University, Nathan, Australia, 12Centre for Health Services Research, Faculty of Medicine, Brisbane, Australia
Biography:
Bertrand Drugeon is a French emergency physician.
He studied medicine in Poitiers, France and specialised in emergency medicine and pre-hospital care.
He started to work at Poitiers University Hospital in 2017. This gave him the opportunity to meet his mentor, Prof. Olivier Mimoz.
In addition to his clinical work, he works on research about skin disinfection and prevention of complications related to vascular access. He is currently a PhD student in France and is a visiting academic at University of Queensland, Brisbane, Australia, where he’s currently working with the AVATAR group and Prof. Claire Rickard’s team.
Abstract:
Introduction
Although Peripheral intravenous catheters (PIVCs) are prevalent in hospitalised patients, they may be complicated by infectious complications leading to morbidity, mortality and increased costs. Our aim was to evaluate chlorhexidine gluconate (CHG)-impregnated dressings for prevention of PIVC related infectious complications.
Methods
A multicentre, randomised controlled cost-effectiveness trial with internal pilot, across three centres in Australia and France. Adults and children aged ≥6 years requiring one PIVC for ≥48 hours were eligible. Patients were randomised to antimicrobial dressings or standard polyurethane dressings. The internal pilot objective was to test protocol feasibility without review of clinical outcomes. Following feasibility assessment, the full trial may be conducted following the same methods. The full trial primary endpoint is a composite of catheter-related infectious complications and phlebitis, since phlebitis may indicate early infection. Ethics approval was obtained and the trial registered (ClinicalTrials.gov NCT05741866).
Results
300 patients (100 France; 200 Australia) were recruited between May 3rd, 2023 and March 27th,2024 for internal pilot and […] were assigned to antimicrobial dressings group and […] to standard care group. The results of the feasibility study are being analysed at the time of submission of the abstract and will be available at the time of the congress.
Conclusion
Prop Trial is the first international randomised study to evaluate the safety, efficacy and cost-effectiveness of an antimicrobial PIVC dressing.